Bone loss in the spondyloarthropathies: Role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies

Advances in Experimental Medicine and Biology

Volumn 649, Issue , 2009, Pages 85-99

  Anandarajah, Allen P ^a   Schwarz, Edward M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLONY STIMULATING FACTOR 1; DICKKOPF 1 PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WNT1 PROTEIN; CYTOKINE;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BONE DENSITY; BONE EROSION; BONE REMODELING; CELL ACTIVATION; CHRONIC INFLAMMATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; ENTEROPATHIC ARTHRITIS; ENTEROPATHY; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; OSSIFICATION; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; SPONDYLOARTHROPATHY; ANIMAL; METABOLISM; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE RESORPTION; CYTOKINES; HUMANS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; SPONDYLARTHROPATHIES;

EID: 70349568508     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0298-6_6     Document Type: Article

References (107)

1. Sinigaglia L, Nervetti A, Mela Q et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian study group on bone mass in rheumatoid arthritis. J Rheumatol 2000; 27:2583-89.
2. Weichselbaum A. The finer changes of cartilage with fungus synovitis and caries of the joint ends (German). Archiv Pathol Anat Physiol Klin Med 1878; 73:461-75.
3. van der Linden S, Valkenburg HA, Cats A et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361-68. (Pubitemid 14134775)
4. Sinigaglia L, Varenna M, Girasole G et al. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin N Am 2006; 32:631-58.
5. Bernstein CN, Blanchard JF, Leslie W et al. The incidence of fracture among patients with inflammatory bowel disease. A population based cohort study. Ann Intern Med 2000; 133:795-99.
6. Harrison BJ, Hutchinson CE, Adams J et al. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 2002; 61:1007-11. (Pubitemid 35221691)
7. Frediani B, Allegri A, Falsetti P et al. Bone mineral density in patients with psoriatic arthritis. J Rheumarol 2001; 28:138-43. (Pubitemid 32062037)
8. Massey HM, Flanagan AM. Human osteoclasts derived form CD 14-positive monocytes. Br J Haematol 1999; 106:167-70. (Pubitemid 29343545)
9. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000:1504-1508.
10. Holliday LS, Welgus HG, Fliszar CJ et al. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 1997; 272:22053-58. (Pubitemid 27382830)
11. Teitelbaum SL. Osteoclasts: What to they do and how do they do it? Am J Pathol 2007; 170:427-435.
12. Vaananen HK, Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995; 108:2729-32.
13. Schett G, Stolina M, Bolon B et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 2005; 52:3192-201. (Pubitemid 41447102)
14. Suzuki Y, Nishikaku F, Nakatuka M et al. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol 1998; 25:1154-60. (Pubitemid 28350891)
15. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-99. (Pubitemid 33062512)
16. Redlich K, Hayer S, Ricci R et al. Osteoclasts are essential for TNF-medicated joint destruction. J Clin Invest 2002; 110:1419-27. (Pubitemid 35396913)
17. Sims NA, Green JR, Glatt M et al. Targeting osteoclasts with zoledronic acid presents bone destruction in collagen induced arthritis. Arthritis Rheum 2004; 50:2338-46. (Pubitemid 38924414)
18. Herrak P, Gortz B, Hayer S et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004; 50:2327-37. (Pubitemid 38924413)
19. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosions in the rheumatoid joint. Arthritis Rheum 1984; 27:968-75. (Pubitemid 14004758)
20. Bromley M, Woolley DE. Histopathology of the rheumatoid lesion; identification of the cell types at sites of cartilage erosion. Arthritis Rheum 1984; 27:857-63. (Pubitemid 14067780)
21. Gravallese EM, Harada Y, Wang JT et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1999; 152:949-51.
22. Gravellese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43:250-56.
23. Fujikawa Y, Shingu M, Torisu T et al. Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Br J Rheumatol 1996; 35:213-17.
24. Suzuki Y, Tsutsumi Y, Nakagawa M et al. Osteoclast-like cells in an in-vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 2001; 40:673-82.
25. Udagawa N, Takahashi N, Akatsu T et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990; 87:7260-64.
26. Fujikawa Y, Sabokbar A, Neale S et al. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996; 55:816-22. (Pubitemid 26392281)
27. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodeling. N Eng J Med 1995; 332:305-11.
28. Hofbauer LC, Khosla S, Dunstan CR et al. The roles of osteoprotogerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12. (Pubitemid 30026926)
29. Crotti TN, Smith MD, Weedon H et al. Receptor activator NF-kB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis and from normal patients: semiquantitative and quantitiative analysis. Ann Rheum Dis 2002; 61:1047-54. (Pubitemid 35397349)
30. Lacey DL, Timms E, Tan H-L et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-76. (Pubitemid 28180851)
31. Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. J Cell Biochem 2006; 97:226-32. (Pubitemid 43167140)
32. Kong YY, Feige U, Sarosi I et al. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoproregerin ligand. Nature 1999; 402:304-09.
33. Lam J, Takeshita S, Barker JE et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-88. (Pubitemid 32038586)
34. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-99. (Pubitemid 33062512)
35. Li P, Schwarz EM, O'Keefe et al. RANK signaling is not required for TNF-mediated increase in CD11 (hi) osteoclast precursors but is essential for mature osteoclast formation in TNF alpha mediated inflammatory arthritis. J Bone Miner Res 2004; 19:207-13. (Pubitemid 38116734)
36. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43:250-58. (Pubitemid 30395732)
37. Takayanagi H, Lizuka H, Juji T et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43:259-69. (Pubitemid 30395733)
38. Hofbauer LC, Schopper M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490-95. (Pubitemid 38988958)
39. Anderson MS, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhances T-cell growth and dendritic cell function. Nature 1997; 390:175-79. (Pubitemid 27507987)
40. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoblast differentiation and activation by osteoproregerin ligand. Proc Natl Acad Sci USA 1989; 96:3540-45.
41. Fata JE, Kong YY, Li J et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103:41-50.
42. Chen G, Sircar K, Aprikian A et al. Expression of RANK/RANKL/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107:289-98. (Pubitemid 44036558)
43. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-24. (Pubitemid 29453612)
44. Kapur RP, Yao Z, Lida MH et al Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. J Bone Miner Res 2004; 19:1689-97. (Pubitemid 41094332)
45. Simonet WA, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19. (Pubitemid 27199902)
46. Kapur RP, Yao Z, Lida MH et al Malignant autosomal recessive osteopetrosis caused by spontaneous mutation of murine Rank. J Bone Miner Res 2004; 19:1689-97. (Pubitemid 41094332)
47. Mizuno A, Kanno T, Hoshi M et al. Transgenic mice over expressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 2002; 20:337-44. (Pubitemid 40645655)
48. Azuma Y, Kaji K, Katogi R et al. Tumor necrosis factor alpha stimulates osteoclast differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275:4858-64. (Pubitemid 30108878)
49. Fitzgerald O, McInnes I. Spondyloarthropathy: disease at the crossroads of immunity. Best Pract Res Clin Rheumatol 2006; 20:949-67. (Pubitemid 44356464)
50. Anandarajah AP, Ritchlin CT. Treatment update on spondyloarthropathy. Curr Opin Rheumatol 2005; 17:247-56.
51. Demis E, Roux C, Breban M et al. Infliximab in Spondyloarthropathy - influence on bone density. Clin Exp Rheumatol 2002; 20:S185-86.
52. Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondyloarthropathy treated with ami-tumour necrosis factor alpha. Ann Rheum Dis 2003; 62:347-49. (Pubitemid 36363442)
53. Joosten LAB, Helsen MMA, van de Loo FAJ et al. Anticyokine treatment of established type II collagen induced arthritis in DBA/1 mice: a comparative study using anti-TNF, anti-IL-1 alpha/beta and IL-1Ra. Arthritis Rheum 1996; 39:797-809.
54. Joosten LAB, Helsen MMA, Saxne T et al. IL-1 alpha blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163:5049-55. (Pubitemid 29501273)
55. Delauren BW, Chu CQ, Filed M et al. Localization of interleukin-1α type 1 interleukin 1 receptor and interleukin 1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992; 31:801-9.
56. Tan AL, Marzo-Ortega H, O'Connor P et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63:1041-45. (Pubitemid 39120352)
57. Haibel H, Rudwaleit M, Listing J et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64:296-98. (Pubitemid 40193630)
58. Gratacos J, Collado A, Pons F et al. Significant loss of bone mass in patients with earlyactive ankylosing spondylitis. Arthritis Rheum 1999; 42:2319-24. (Pubitemid 30333411)
59. Yoshida H, Hayashi S-I, Kunisada T et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345:442-44. (Pubitemid 120014957)
60. Yang PT, Kasai H, Xiao WG et al. Increased expression of macrophage colony stimulating factor in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 2006; 65:1671-72. (Pubitemid 44799690)
61. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-37.
62. Chabaud M, Durand JM, Buchs et al. A T-cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42;963-70. (Pubitemid 29215007)
63. Kotake S, Udagawa T, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-52. (Pubitemid 29218305)
64. McInnes IB, Leung BP, Sturrock RD et al. Interleukin-15 mediated T-cell-dependent regulation of tumor necrosis factor alpha production in rheumatoid arthritis. Nat Med 1997; 3:189-95. (Pubitemid 27064704)
65. Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumor necrosis factor α. Ann Rheum Dis 2003; 62:347-49. (Pubitemid 36363442)
66. Amor B, Santos RS, Nahal R et al. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21:1883-87. (Pubitemid 24312652)
67. Francois RJ, Neure L, Sieper J et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor a in two patients with early disease and transforming growth factor b in three more advanced cases. Ann Rheum Dis 2006; 65:713-20. (Pubitemid 43799168)
68. Marzo-Ortega H, O'Connor P, Emery P et al. Sacroiliac joint biopsies in early sacroilitis. Rheumatol 2007; 46:1210-11. (Pubitemid 47050632)
69. Braun J, Bollow M, Konig H et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499-05.
70. Appel H, Kuhne M, Spiekermann S et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845-51. (Pubitemid 44497763)
71. Appel H, Kuhne M, Spiekermann S et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis. Arthritis Rheum 2006; 54:1805-13.
72. Cunnane G, Bresnihan B, Fitzgerald O. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis Rheum 1998; 41:180-82. (Pubitemid 28041939)
73. Baraliakos X, Listing J, Brandt H et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007; 46:1450-3. (Pubitemid 47317093)
74. Baraliakos X, Listing J, Rudwaleit M et al. Radiographic progression in patients with ankylosing spondylicis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005; 64:1462-6. (Pubitemid 41623858)
75. Schett G, Landewe R, van der Heidje D. Tumor necrosis factor blockers and structural remodeling in ankylosing spondylitis: what is reality and what is fiction. Ann Rheum Dis 2007; 66:709-11. (Pubitemid 46846687)
76. Mitra D, Elvins DM, Spenden DJ et al. The prevalence of vertebral compression fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford) 2000; 39:85-9. (Pubitemid 30095412)
77. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 2004; 71:291-95. (Pubitemid 39037316)
78. Will R, Bhalla AK, Palmer R et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 1989; 11:1483-85. (Pubitemid 20018143)
79. Gratacos J, Collado A, Pons F et al. Significant loss of bone in patients with early active ankylosing spondylitis. Arthritis Rheum 1999; 42:2319-24. (Pubitemid 30333411)
80. Kim H-R, Kim H-Y, Lee S-H. Elevated levels of soluble receptor activator of nuclear factor-κB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006; 45:1197-00. (Pubitemid 44542059)
81. Crotti TN, Smith MD, Weedon H et al. Receptor activator NF-kB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61:1047-54. (Pubitemid 35397349)
82. Haynes DR, Barg E, Crotti TN et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatol 2003; 42:123-34. (Pubitemid 36131578)
83. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004; 31:2236-41. (Pubitemid 39453245)
84. Grisar J, Bernecker PM, Aringer M et al. Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29:1430-36. (Pubitemid 34755610)
85. Golmia RP, Sousa BD, Scheinberg MA. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacos et al. Arthritis Rheum 2002; 46:3390-91.
86. Gladman DD, Schukett R, Russell ML et al. QJ Med 1987; 62:127-41.
87. Torre Alonso JC, Perez RA, Castrillo AJM et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30:245-50.
88. Kane D, Stafford L, Bresnihan B et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheuamtology (Oxford) 2003; 42:1460-68. (Pubitemid 37508919)
89. Ritchlin CT, Haas-Smith SA, Li P et al. Mechanisms of anti-TNF-alpha and RANKL mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-31. (Pubitemid 37074957)
90. Anandarajah AP, Schwarz EM, Totterman S et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow edema in parients with psoriatic arthritis. Ann Rheum Dis (in press).
91. Reddy SM, Reed G, Anandarajah AP et al. Comparative analysis of disease activity, radiographic features and bone density in psoriatic and rheumatoid arthritis. Arthritis Rheum 2005; 52:S1726.
92. Dinca M, Fries W, Luisetto G et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999; 94:1292-97. (Pubitemid 29214644)
93. De Keyser F, Elewant D, De Vos M et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24:785-13.
94. Lin CL, Moniz C, Chambers TJ et al. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111:1263-71. (Pubitemid 26362251)
95. Ashcroft AJ, Cruickshank SM, Croucher PI et al. Colonic dendritic cells, intestinal inflammation and T-cell mediated bone destruction are modulated by recombinant osteoportogerin. Immunity 2003; 19:849-61. (Pubitemid 37542305)
96. Fuss IJ. Cytokine network in inflammatory bowel disease. Curr Drug Targets Inflamm Allerhy 2003; 2:101-12.
97. Westerholm-Ormio M, Garioch J, Ketola I et al. Inflammatory cytokines in small intestinal mucosa of parients with potential coeliac disease. Clin Exp Immunol 2002; 128:94-01. (Pubitemid 34451185)
98. Ryan BM, Russel MG, Schutgers L et al. Effect of antitumor necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease : a prospective study. Aliment Pharmacol Ther 2004; 20:851-57. (Pubitemid 39424892)
99. Pazianas M, Rhim AD, Weinberg AM et al. The effect of anti-TNF-α therapy on spinal bone mineral density in patients with Crohn's disease. Ann NY Acad Sci 2006; 1068:543-46.
100. Moschen AR, Kaser A, Enrich B et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479-487. (Pubitemid 40395499)
101. Kemppainen T, Kroger H, Janatuinen E et al. Osteoporosis in adult patients with celiac disease. Bone 2002; 24:249-255.
102. Koneakou M, Przemiosio RT, Sturgess RP et al. Expression of tumor necrosis factor-alpha, interleukin-6 and interleukin-2 mRNA in the jejunum of patients with celiac disease. Scand J Gastroenterol 1996; 30:456-463.
103. Fornan MC, Pedreira S, Niveloni S et al. Pre- and posttrearment serum levels of cytokines IL-1 beta, IL-6 and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am J Gastroenterol 1998; 93:413-418. (Pubitemid 29068348)
104. Taranta A, Fortunati D, Longo M et al. Imbalance of osteoclastogenesis- regulating factors in patients with celiac disease. J Bone Miner Res 2004; 19:1112-1121. (Pubitemid 41110563)
105. Baeten D, Demetter P, Cuvelier CA et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathies. J Pathol 2002; 196:343-350. (Pubitemid 34189425)
106. Inman RD, Chiu B. Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats. Arthritis Rheum 2006; 53:499-507. (Pubitemid 43228624)
107. Butrimiene I, Jarmalaite S, Ranceva J et al. Different cytokine profiles in patients wirh chronic and acute reactive arthritis. Rheumatol 2004; 43:1300-1304. (Pubitemid 39359308)